Sorafenib acts synergistically in combination with radiotherapy without causing intestinal damage in colorectal cancer

Tumori

Volumn 99, Issue 2, 2013, Pages 176-182

  Jeong, Youn Kyoung ^a,b   Kim, Mi Sook ^a   Lee, Ji Young ^a   Kim, Eun Ho ^a   Kim, Wonwoo ^a   Ha, Hunjoo ^b   Jeong, Jae Hoon ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Ewha Womans University   (South Korea)

Author keywords

Colorectal cancer; G2 M arrest; Gamma radiation; Jejunum crypt; Radiosensitive effect; Sorafenib

Indexed keywords

RADIOSENSITIZING AGENT; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; CESIUM; DRUG DERIVATIVE; NICOTINAMIDE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CELL CYCLE; COLON ADENOCARCINOMA; COLONY FORMING UNIT M; COLORECTAL CANCER; COMET ASSAY; CONTROLLED STUDY; DNA REPAIR; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CRYPT; INTESTINE INJURY; IONIZING RADIATION; JEJUNUM; M PHASE CELL CYCLE CHECKPOINT; RADIOSENSITIVITY; TUMOR XENOGRAFT; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ANIMAL; C57BL MOUSE; COLON; COLORECTAL TUMOR; DRUG EFFECT; DRUG SCREENING; FEMALE; FLOW CYTOMETRY; MALE; MIDDLE AGED; MOUSE; NUDE MOUSE; RADIATION DOSE; RADIATION EXPOSURE; RECTUM; TUMOR CELL LINE; XENOGRAFT;

ADENOCARCINOMA; ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CESIUM RADIOISOTOPES; CHEMOTHERAPY, ADJUVANT; COLON; COLORECTAL NEOPLASMS; COMET ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; RECTUM; TRANSPLANTATION, HETEROLOGOUS; TUMOR STEM CELL ASSAY;

MLCS; MLOWN;

EID: 84881258962     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1283.14189     Document Type: Article

References (21)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127: 2893-2917, 2010.
2. Andre N, Schmiegel W: Chemoradiotherapy for colorectal cancer. Gut, 54: 1194-1202, 2005.
3. Augustine CK, Toshimitsu H, Jung SH, Zipfel PA, Yoo JS, Yoshimoto Y, Selim MA, Burchette J, Beasley GM, McMahon N: Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Therapeut, 9: 2090-2101, 2010.
4. Dal Lago L, D'Hondt V, Awada A: Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist, 13: 845-858, 2008.
5. Azad N, Annunziata C, Barrett T, Chen C, Steinberg S, Kwitkowski V, McNally D, Kotz H, Minasian L, Kohn E: Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: clinical and translational results. J Clin Oncol, 25: 3542, 2007.
6. Horgan AM, Dawson LA, Swaminath A, Knox JJ: Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma. J Gastroint Cancer, 2010.
7. Kasibhatla M, Steinberg P, Meyer J, Ernstoff MS, George DJ: Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. Clin Genitourinary Cancer, 5: 291-294, 2007.
8. Oh H, Seong J, Kim W, Park S, Koom WS, Cho NH, Song M: Recombinant human epidermal growth factor (rhEGF) protects radiation-induced intestine injury in murine system. J Radiat Res: 1007: 150-159, 2010.
9. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Therapeut, 7: 3129, 2008.
10. Montagut C, Settleman J: Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett, 283: 125-134, 2009.
11. Suen AW, Galoforo S, Marples B, McGonagle M, Downing L, Martinez AA, Robertson JM, Wilson GD: Sorafenib and radiation: a promising combination in colorectal cancer. Int J Radiat Oncol Biol Physics, 78: 213-220, 2010.
12. Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J, Cerniglia G, Rajendran RR, Gupta A, Rustgi AK: Cell cycle-dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res, 67: 9443-9454, 2007.
13. Heim M, Scharifi M, Zisowsky J, Jaehde U, Voliotis D, Seeber S, Strumberg D: The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs, 16: 129, 2005.
14. Kuo YC, Lin WC, Chiang IT, Chang YF, Chen CW, Su SH, Chen CL, Hwang JJ: Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-kappaB expression in vitro and in vivo. Biomed Pharmacother, 66: 12- 20, 2012.
15. Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, Wirth T, Schemmer P, Buchler MW, Zoller M, Salnikov AV, Herr I: Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res, 70: 5004-5013, 2010.
16. Yadav A, Kumar B, Teknos TN, Kumar P: Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther, 10: 1241-1251, 2011.
17. Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, McCubrey JA, Montalto G: Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle, 11: 2843- 2855, 2012.
18. Niyazi M, Maihoefer C, Krause M, Rodel C, Budach W, Belka C: Radiotherapy and "new" drugs - new side effects? Radiat Oncol, 6: 177, 2011.
19. Peters NA, Richel DJ, Verhoeff JJ, Stalpers LJ: Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol, 26: 2405-2406, 2008.
20. Diaz O, Mazeron R, Martin E, Carrie C: Toxicity of radiation therapy and antiangiogenics combination: a case report. Cancer Radiother, 13: 205-208, 2009.
21. Al-Mulla F, Hagan S, Behbehani AI, Bitar MS, George SS, Going JJ, García JJC, Scott L, Fyfe N, Murray GI: Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol, 24: 5672-5679, 2006.